Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
Evolving role of regorafenib for the treatment of advanced cancers — Axel Grothey (2020) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Evolving role of regorafenib for the treatment of advanced cancers
Shared by
Jean Yves Blay
Evolving role of regorafenib for the treatment of advanced cancers
Article
2020
en
Authors
+2 more
AG
Axel Grothey
Jean Yves Blay
NP
Nick Pavlakis
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2022
Regorafenib for the Treatment of Sarcoma
Jean Yves Blay
,
Florence Duffaud
,
Suzanne George
,
Robert G. Maki
,
Nicolas Penel
Article
2007
The evolving role of lenalidomide in the treatment of hematologic malignancies
Efstathios Kastritis
,
Meletios A Dimopoulos
Article
2011
The emerging important role of microRNAs in the pathogenesis, diagnosis and treatment of human cancers
James S. Wilmott
,
Xu Dong Zhang
,
Peter Hersey
,
Richard A Scolyer
Article
2022
Regorafenib versus Cabozantinib as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: An Anchored Matching-Adjusted Indirect Comparison of Efficacy and Safety
Philippe Merle
,
Masatoshi Kudo
,
Stanimira Krotneva
,
Kirhan Özgürdal
,
Yun Su
,
Irina Proskorovsky
Dataset
Supplementary Material for: Regorafenib vs. cabozantinib as second-line treatment for advanced hepatocellular carcinoma: an anchored matching-adjusted indirect comparison of efficacy and safety
Philippe Merle
,
Masatoshi Kudo
,
Stanimira Krotneva
,
Kirhan Özgürdal
,
Su Y.
,
Irina Proskorovsky
Discussion(0)
No comments yet. Be the first to comment.